In this real-world study, we compared the effects of liraglutide, semaglutide, and tirzepatide on weight loss and metabolic parameters over a 36-week period in non-diabetic individuals with overweight or obesity
If you are interested in pursuing these medications for weight loss (and potentially gaining other health benefits as well), please contact us to make an appointment
Daly, C
If travelling to countries with extreme temperatures, consult your pharmacist about specialised cooling solutions
Do we have a new antihypertensive agent here
Heart failure therapy by GLP-1RAs Although a meta-analysis of large-scale clinical trials suggested that GLP-1RAs reduce heart failure hospitalizations (HHF) by approximately 10% in patients with diabetes at high cardiovascular risk [22, 23], the treatment effects on the risk of HHF in individual trials other than AMPLITUDE-O were not significant (Tables 1, 2)